Oseltamivir in the management of influenza

被引:16
作者
Oxford, J [1 ]
机构
[1] Univ London, Queen Mary, Retroscreen Virol Ltd, London E1 4NS, England
关键词
epidemic; influenza; oseltamivir; pandemic;
D O I
10.1517/14656566.6.14.2493
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Seasonal influenza causes significant morbidity and mortality in adults and children. However, a worldwide influenza pandemic could cause considerably more deaths (20 - 40 million) and would majorly disrupt everyday life in most countries. Oseltamivir has proven to be safe and effective for the prevention or treatment of all known influenza subtypes, reducing the severity and duration of symptoms, the complications arising from influenza infection (pneumonia, hospitalisation, antibiotic use) and mortality. Oseltamivir has been shown to be effective against pandemic strains of influenza, including the currently circulating strain (H5N1). As a result, the World Health Organization has recommended the stockpiling of oseltamivir in the event of an influenza pandemic.
引用
收藏
页码:2493 / 2500
页数:8
相关论文
共 50 条
[21]   Influenza viruses resistant to the antiviral drug oseltamivir: Transmission studies in ferrets [J].
Herlocher, ML ;
Truscon, R ;
Elias, S ;
Yen, HL ;
Roberts, NA ;
Ohmit, SE ;
Monto, AS .
JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (09) :1627-1630
[22]   Influenza virus carrying an R292K mutation in the neuraminidase gene is an transmitted in ferrets [J].
Herlocher, ML ;
Carr, J ;
Ives, J ;
Elias, S ;
Truscon, R ;
Roberts, N ;
Monto, AS .
ANTIVIRAL RESEARCH, 2002, 54 (02) :99-111
[23]   Avian influenza - A challenge to global health care structures [J].
Hien, TT ;
de Jong, M ;
Farrar, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (23) :2363-2365
[24]   STIMULATION OF TUMOR-NECROSIS-FACTOR SECRETION BY PURIFIED INFLUENZA-VIRUS NEURAMINIDASE [J].
HOUDE, M ;
ARORA, DJS .
CELLULAR IMMUNOLOGY, 1990, 129 (01) :104-111
[25]   The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo [J].
Ives, JAL ;
Carr, JA ;
Mendel, DB ;
Tai, CY ;
Lambkin, R ;
Kelly, L ;
Oxford, JS ;
Hayden, FG ;
Roberts, NA .
ANTIVIRAL RESEARCH, 2002, 55 (02) :307-317
[26]  
Jefferson T, 2004, COCHRANE DB SYST REV, V3
[27]   Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations [J].
Kaiser, L ;
Wat, C ;
Mills, T ;
Mahoney, P ;
Ward, P ;
Hayden, F .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (14) :1667-1672
[28]   Resistant influenza A viruses in children treated with oseltarnivir: descriptive study [J].
Kiso, M ;
Mitamura, K ;
Sakai-Tagawa, Y ;
Shiraishi, K ;
Kawakami, C ;
Kimura, K ;
Hayden, FG ;
Sugaya, N ;
Kawaoka, Y .
LANCET, 2004, 364 (9436) :759-765
[29]  
Klenk H D, 1988, Adv Virus Res, V34, P247, DOI 10.1016/S0065-3527(08)60520-5
[30]   Oseltamivir distributes to influenza virus replication sites in the middle ear and sinuses [J].
Kurowski, M ;
Oo, C ;
Wiltshire, H ;
Barrett, J .
CLINICAL DRUG INVESTIGATION, 2004, 24 (01) :49-53